Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa, PhD, Lennert J. Veerman, MD, PhD, Melanie Bertram, PhD, Stephen S. Lim, PhD, Nathorn Chaiyakunnaphruk, PhD, Theo Vos, PhD Value in Health Regional Issues Volume 1, Issue 1, Pages 15-22 (May 2012) DOI: 10.1016/j.vhri.2012.03.019 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Cardiovascular disease prevention model. CVD, cardiovascular disease; IHD, ischemic heart disease. Value in Health Regional Issues 2012 1, 15-22DOI: (10.1016/j.vhri.2012.03.019) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Intervention pathway of lifetime DALYs averted and total costs associated with the ideal mix of blood pressure- and cholesterol-lowering drugs for cardiovascular disease prevention in Thailand. BP, blood pressure; DALY, disability-adjusted life-years. Value in Health Regional Issues 2012 1, 15-22DOI: (10.1016/j.vhri.2012.03.019) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions